- Home
- GRI vs ELAB Comparison
GRI vs ELAB Comparison
Compare GRI & ELAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRI
- ELAB
- Stock Information
- Founded
- GRI 2018
- ELAB 2020
- Country
- GRI United States
- ELAB United States
- Employees
- GRI N/A
- ELAB N/A
- Industry
- GRI Biotechnology: Pharmaceutical Preparations
- ELAB
- Sector
- GRI Health Care
- ELAB
- Exchange
- GRI Nasdaq
- ELAB Nasdaq
- Market Cap
- GRI 3.4M
- ELAB 3.2M
- IPO Year
- GRI N/A
- ELAB 2023
- Fundamental
- Price
- GRI $1.80
- ELAB $2.33
- Analyst Decision
- GRI Strong Buy
- ELAB
- Analyst Count
- GRI 2
- ELAB 0
- Target Price
- GRI $22.00
- ELAB N/A
- AVG Volume (30 Days)
- GRI 143.8K
- ELAB 221.7K
- Earning Date
- GRI 08-13-2025
- ELAB 08-13-2025
- Dividend Yield
- GRI N/A
- ELAB N/A
- EPS Growth
- GRI N/A
- ELAB N/A
- EPS
- GRI N/A
- ELAB N/A
- Revenue
- GRI N/A
- ELAB N/A
- Revenue This Year
- GRI N/A
- ELAB N/A
- Revenue Next Year
- GRI N/A
- ELAB N/A
- P/E Ratio
- GRI N/A
- ELAB N/A
- Revenue Growth
- GRI N/A
- ELAB N/A
- 52 Week Low
- GRI $1.10
- ELAB $1.95
- 52 Week High
- GRI $43.69
- ELAB $756.00
- Technical
- Relative Strength Index (RSI)
- GRI 65.05
- ELAB 63.32
- Support Level
- GRI $1.53
- ELAB $2.18
- Resistance Level
- GRI $1.75
- ELAB $2.89
- Average True Range (ATR)
- GRI 0.13
- ELAB 0.18
- MACD
- GRI 0.06
- ELAB 0.05
- Stochastic Oscillator
- GRI 89.55
- ELAB 61.82
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
About ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.